Rating Rationale
June 06, 2024 | Mumbai
 
Sanjivani Paranteral Limited
Ratings migrated to 'CRISIL B+/Stable/CRISIL A4'
 
Rating Action
Total Bank Loan Facilities Rated Rs.65.5 Crore
Long Term Rating CRISIL B+/Stable (Migrated from 'CRISIL D ISSUER NOT COOPERATING*')
Short Term Rating CRISIL A4 (Migrated from 'CRISIL D ISSUER NOT COOPERATING*')
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities
*Issuer did not cooperate; based on best-available information

 

Detailed Rationale

Due to inadequate information, CRISIL Ratings, in line with SEBI guidelines, had migrated the rating of Sanjivani Paranteral Limited (SPL; Part of Sanjivani Group) to CRISIL D/CRISIL D Issuer Not Cooperating'. However, the management has subsequently started sharing requisite information, necessary for carrying out comprehensive review of the rating. Consequently, CRISIL Rating is migrating the ratings on bank facilities of SPL to CRISIL B+/Stable/CRISIL A4 from 'CRISIL D/CRISIL D Issuer Not Cooperating'.

 

The rating reflects modest scale of operations and vulnerability of profitability to adverse changes in government regulations. These weaknesses are offset by extensive industry experience of the promoters and moderate financial risk profile.

Analytical Approach

For arriving at the ratings, CRISIL Ratings have consolidated the business and financial risk profile of SPL and SPL Infusion Private Limited (SPLIPL) collectively referred to as the sanjivani group as they are in the similar line of business and have significant operational and financial linkages.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Weaknesses:

  • Vulnerability of profitability to adverse changes in government regulations: The pharmaceutical industry is highly regulated by state governments and various government agencies such as Central Drugs Standard Control Organization and National Pharmaceutical Pricing Authority. These agencies approve new drugs and clinical trials, control the quality of imported drugs, and set prices for many critical drugs; while state authorities regulate manufacture, sales, and distribution.

 

  • Modest scale of operation: Group has a modest scale of operations of Rs 54 crores for fiscal 2024. The group is expanding into newer geographies and expanding its product profile which will support scale going forward. Further Group has started a JV with Hindustan Antibiotics Limited which would further support the improvement in revenue. Going forward the scale of operations is expected to improve and will remain key monitorable.

 

Strengths:

  • Extensive industry experience of the promoters: The promoters have experience of over 30 years in the Pharmaceuticals - Formulation industry. This has given them an understanding of the dynamics of the market and enabled them to establish relationships with suppliers and customers.

 

  • Moderate financial risk profile: Group’s Financial risk profile is comfortable marked by lower reliance on external debt. Group has moderate networth of Rs 27.89 crores as on March 31,2024. Capital structure is strong marked by gearing of 0.03 times and comfortable debt protection metrics marked by interest coverage of more than 36 times as on March 31, 2024. With steady accretion to reserves and lower reliance on external debt and no major plans of debt funded capex, financial risk profile is expected to remain comfortable over the medium term and will remain key monitorable.

Liquidity: Stretched

Company was classified as NPA by banks due to delay in repayment. The group did one time settlement with bank and all the dues were cleared in April 2023. The group currently has no outstanding debt. Net cash accruals for fiscal 2024 were Rs 7.1 Crores. Going forward accruals are expected to be over Rs 10 crores. Support in the form of equity or unsecured loan will be infused by the promoters whenever required.

Outlook: Stable

CRISIL Ratings believe SPL will continue to benefit from the extensive experience of its promoter, and established relationships with clients.

Rating Sensitivity factors

Upward factors:

  • Sustained improvement in scale of operation by over 20% and sustenance of operating margin, leading to higher cash accruals.
  • Improvement in working capital cycle.

 

Downward factors:

  • Decline in net cash accruals below Rs 5 crore on account of decline in revenue or operating profits.
  • Large debt-funded capital expenditure weakens capital structure.
  • Witnesses a substantial increase in its working capital requirements thus weakening its liquidity & financial profile.

About the Group

Incorporated in 1994, Sanjivani group manufactures mainly injectables in the antibiotics segment, and branded capsules, tablets, and formulations. The company is promoted by Mr. Ashwin Khemka.

Key Financial Indicators

As on / for the period ended March 31

Unit

2024

2023

Operating income

Rs crore

54.93

36.04

Reported profit after tax

Rs crore

6.16

4.51

PAT margins

%

11.21

12.51

Adjusted Debt/Adjusted Net worth

Times

0.03

(0.81)

Interest coverage

Times

34.67

16.06

Any other information: Not Applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name of the instrument Date of
Allotment
Coupon
Rate (%)
Maturity
Date
Issue size
(Rs. Crore)
Complexity
Level
Rating assigned
with outlook
NA Proposed Fund-Based Bank Limits NA NA NA 32 NA CRISIL B+/Stable
NA Proposed Non Fund based limits NA NA NA 33.5 NA CRISIL A4

Annexure – List of entities consolidated

Names of Entities Consolidated

Extent of Consolidation

Rationale for Consolidation

Sanjivani Paranteral Limited

Full

Similar line of business, business, and financial linkages

SPL Infusion Private Limited

Full

Similar line of business, business, and financial linkages

Annexure - Rating History for last 3 Years
  Current 2024 (History) 2023  2022  2021  Start of 2021
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 32.0 CRISIL B+/Stable   -- 31-03-23 CRISIL D (Issuer Not Cooperating)* 31-01-22 CRISIL D (Issuer Not Cooperating)*   -- CRISIL D (Issuer Not Cooperating)*
Non-Fund Based Facilities ST 33.5 CRISIL A4   -- 31-03-23 CRISIL D (Issuer Not Cooperating)* 31-01-22 CRISIL D (Issuer Not Cooperating)*   -- CRISIL D (Issuer Not Cooperating)*
All amounts are in Rs.Cr.
* - Issuer did not cooperate; based on best-available information
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Rating
Proposed Fund-Based Bank Limits 32 CRISIL B+/Stable
Proposed Non Fund based limits 33.5 CRISIL A4
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Himank Sharma
Director
CRISIL Ratings Limited
D:+91 124 672 2152
himank.sharma@crisil.com


Rushabh Pramod Borkar
Associate Director
CRISIL Ratings Limited
D:+91 22 3342 3390
rushabh.borkar@crisil.com


Aditya Shah
Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Aditya.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html